Hot Stocks Report: Vertex Pharmaceuticals Incorporated (VRTX), Sage Therapeutics, Inc. (SAGE)

Vertex Pharma

Vertex Pharma

Skandinaviska Enskilda Banken AB publ's holdings in Vertex Pharmaceuticals were worth $12,590,000 as of its most recent SEC filing. Moving averages are used as a strong indicator for technical stock analysis and it helps investors in figuring out where the stock has been and also facilitate in determining where it may be possibly heading. Oakmont Partners LLC acquired a new position in shares of Vertex Pharmaceuticals during the first quarter worth about $219,000. Following the completion of the sale, the executive vice president now directly owns 145,061 shares of the company's stock, valued at $18,576,511.66. Finally, First Manhattan Co. raised its stake in shares of Vertex Pharmaceuticals by 1.3% in the first quarter. Capstone Asset Management Co. increased its position in shares of Vertex Pharmaceuticals by 0.9% in the first quarter. Cambridge Rech Inc owns 0.01% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 6,300 shares. Swiss National Bank now owns 878,809 shares of the pharmaceutical company's stock valued at $96,098,000 after buying an additional 189,000 shares in the last quarter. FUKOKU MUTUAL LIFE INSURANCE Co increased its stake in shares of Vertex Pharmaceuticals by 7.1% in the first quarter. Canal Insurance CO now owns 40,000 shares of the pharmaceutical company's stock worth $2,947,000 after buying an additional 20,000 shares during the period.

Vertex Pharmaceuticals Incorporated (NASDAQ VRTX) traded up 2.41% during mid-day trading on Friday, reaching $163.17. Stifel Corporation accumulated 29,987 shares or 0.01% of the stock. The firm has a market cap of $39.77 billion, a price-to-earnings ratio of 222.710 and a beta of 1.74. The stock's 50 day moving average is $128.18 and its 200 day moving average is $106.43.

Vertex Pharmaceuticals Incorporated (VRTX) now trades with a market capitalization of $39.75 Billion. The pharmaceutical company reported $0.13 EPS for the quarter, beating analysts' consensus estimates of $0.04 by $0.09. The business had revenue of $714.72 million during the quarter, compared to analysts' expectations of $692.64 million. Vertex Pharmaceuticals had a net margin of 8.64% and a return on equity of 3.00%. The firm's revenue for the quarter was up 79.5% compared to the same quarter past year. Leerink Swann analyst G. Porges now forecasts that the pharmaceutical company will post earnings per share of $0.14 for the quarter, down from their previous forecast of $0.16.

ILLEGAL ACTIVITY NOTICE: "Vertex Pharmaceuticals Incorporated (VRTX) Upgraded to "Buy" at Zacks Investment Research" was first posted by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of global trademark and copyright legislation. The original version of this news story can be viewed at

Several equities research analysts recently commented on VRTX shares. Finally, Oppenheimer Holdings, Inc. reiterated a "hold" rating on shares of Vertex Pharmaceuticals in a research report on Sunday, April 30th. Vetr upgraded shares of Vertex Pharmaceuticals from a "strong sell" rating to a "strong-buy" rating and set a $156.00 price target on the stock in a research report on Tuesday. Stifel Nicolaus upped their price objective on Vertex Pharmaceuticals from $130.00 to $154.00 and gave the company a buy rating in a report on Tuesday. Four equities research analysts have rated the stock with a hold rating, twenty-three have given a buy rating and one has assigned a strong buy rating to the stock. H.C. Wainwright upgraded it to "Buy" rating and $155 target in Friday, October 30 report.

In other news, EVP Michael Parini sold 10,829 shares of the stock in a transaction dated Wednesday, July 19th.

Canyon Advsr invested in 494,194 shares or 1.22% of the stock. The price of the stock has increased by 1.37% since. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

In other Vertex Pharmaceuticals news, CEO Jeffrey M. Leiden sold 157,200 shares of the company's stock in a transaction that occurred on Friday, April 28th.

EVP\Chief Commercial Officer Stuart A Arbuckle sold 101,875 shares of VRTX stock on 07/21/2017 at the average price of $161.5. The disclosure for this sale can be found here. Insiders sold 884,674 shares of company stock valued at $127,947,355 over the last quarter.

Vertex Pharmaceuticals Incorporated has a 52-week low of $71.46 and a 52-week high of $167.00. The Firm is focused on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs in other indications.

Recommended News

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.